• Je něco špatně v tomto záznamu ?

Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma

T. Zemanek, B. Melichar, M. Lovecek, P. Soucek, B. Mohelnikova-Duchonova,

. 2019 ; 20 (2) : 113-127. [pub] 20181212

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006692

Grantová podpora
NV16-28375A MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek

E-zdroje Online Plný text

NLK PubMed Central od 2015 do Před 1 rokem
ProQuest Central od 2000-02-01 do 2020-12-31
Health & Medicine (ProQuest) od 2000-02-01 do 2020-12-31

Odkazy

PubMed 30539680
DOI 10.2217/pgs-2018-0073
Knihovny.cz E-zdroje

Pancreatic carcinoma is usually diagnosed late when treatment options are limited and is considered a chemo-resistant malignancy. However, early stage, good performance status and specific patient subgroup are thought to have a more favorable prognosis. Search for novel molecular biomarkers, which could predict treatment resistance, represents a major opportunity, but also a challenge in further research. This review summarizes most aspects of individualized therapy of pancreatic cancer including promising biomarkers, BRCA-deficient pancreatic cancer and its etiology. It may be estimated that nearly a third of metastatic pancreatic ductal adenocarcinoma patients could benefit from treatment other than gold standard chemotherapy. Thus, other aspects of an individualized approach concerning the main factors for the choice of the best therapy for individual pancreatic cancer patient (surgery and chemotherapy), as well as the future directions (target therapy and immunotherapy), are also addressed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006692
003      
CZ-PrNML
005      
20200526110226.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/pgs-2018-0073 $2 doi
035    __
$a (PubMed)30539680
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Zemanek, Tomas $u Department of Oncology, Faculty of Medicine & Dentistry, Palacky University Olomouc, University Hospital Olomouc, Czech Republic.
245    10
$a Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma / $c T. Zemanek, B. Melichar, M. Lovecek, P. Soucek, B. Mohelnikova-Duchonova,
520    9_
$a Pancreatic carcinoma is usually diagnosed late when treatment options are limited and is considered a chemo-resistant malignancy. However, early stage, good performance status and specific patient subgroup are thought to have a more favorable prognosis. Search for novel molecular biomarkers, which could predict treatment resistance, represents a major opportunity, but also a challenge in further research. This review summarizes most aspects of individualized therapy of pancreatic cancer including promising biomarkers, BRCA-deficient pancreatic cancer and its etiology. It may be estimated that nearly a third of metastatic pancreatic ductal adenocarcinoma patients could benefit from treatment other than gold standard chemotherapy. Thus, other aspects of an individualized approach concerning the main factors for the choice of the best therapy for individual pancreatic cancer patient (surgery and chemotherapy), as well as the future directions (target therapy and immunotherapy), are also addressed.
650    _2
$a adenokarcinom $x farmakoterapie $x genetika $x imunologie $x patologie $7 D000230
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a chemorezistence $x genetika $x imunologie $7 D019008
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $7 D007167
650    _2
$a cílená molekulární terapie $7 D058990
650    _2
$a nádory slinivky břišní $x farmakoterapie $x genetika $x imunologie $x patologie $7 D010190
650    12
$a individualizovaná medicína $7 D057285
650    _2
$a signální transdukce $x účinky léků $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Faculty of Medicine & Dentistry, Palacky University Olomouc, University Hospital Olomouc, Czech Republic. Institute of Molecular & Translational Medicine, Faculty of Medicine & Dentistry, Palacky University, Olomouc, Czech Republic.
700    1_
$a Lovecek, Martin $u Department of Surgery I, Faculty of Medicine & Dentistry, Palacky University, Olomouc, University Hospital Olomouc, Czech Republic.
700    1_
$a Soucek, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Mohelnikova-Duchonova, Beatrice $u Department of Oncology, Faculty of Medicine & Dentistry, Palacky University Olomouc, University Hospital Olomouc, Czech Republic. Institute of Molecular & Translational Medicine, Faculty of Medicine & Dentistry, Palacky University, Olomouc, Czech Republic.
773    0_
$w MED00008477 $t Pharmacogenomics $x 1744-8042 $g Roč. 20, č. 2 (2019), s. 113-127
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30539680 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526110223 $b ABA008
999    __
$a ok $b bmc $g 1525550 $s 1096748
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 20 $c 2 $d 113-127 $e 20181212 $i 1744-8042 $m Pharmacogenomics $n Pharmacogenomics $x MED00008477
GRA    __
$a NV16-28375A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace